Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Biology of Blood and Marrow Transplantation

• Publication date

  1997-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 9209739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• NK cell‐based immunotherapy for hepatocellular carcinoma: Challenges and opportunities

  2025cites this paper
• Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation

  2025cites this paper
• Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

  2024cites this paper
• Novel insights into immune cells modulation of tumor resistance.

  2024cites this paper
• Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective

  2024cites this paper
• IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside.

  2024cites this paper
• TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer

  2023cites this paper
• An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood

  2023cites this paper
• Harnessing the Power of Memory-like NK Cells to Fight Cancer.

  2023cites this paper
• Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics

  2023cites this paper
• Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

  2023cites this paper
• NK Cell-Based Immunotherapy in Colorectal Cancer

  2022cites this paper
• Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

  2022cites this paper
• Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity

  2022cites this paper
• The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)

  2022cites this paper
• Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors

  2022cites this paper
• Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

  2022cites this paper
• NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms

  2021cites this paper
• Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma

  2021cites this paper
• Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity

  2021cites this paper
• Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

  2021cites this paper
• NK cells and ILCs in tumor immunotherapy.

  2020cites this paper
• Manufacturing of natural killer cells for treating solid malignancies

  2020cites this paper
• Current progress in cancer immunotherapy based on natural killer cells

  2020cites this paper
• Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B‐ and T‐cell acute lymphoblastic leukaemia

  2020cites this paper
• Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside

  2019cites this paper
• Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis

  2019cites this paper
• Natural Killer Cells in Cancer Immunotherapy

  2019cites this paper
• NK Cell-Based Immunotherapy for Hematological Malignancies

  2019cites this paper
• Chapter 22 – Natural Killer Cell Immunity

  2018cites this paper
• NK Cell and NKT Cell Immunotherapy

  2018cites this paper
• NK cell therapy for hematologic malignancies

  2018cites this paper
• Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?

  2018cites this paper
• Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

  2018cites this paper
• Immunotherapy for Pediatric Malignancies

  2017cites this paper
• Natural killer cells as a promising tool to tackle cancer—A review of sources, methodologies, and potentials

  2017cites this paper
• Can we make a better match or mismatch with KIR genotyping?

  2016cites this paper
• A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

  2016cites this paper
• Adoptive Cellular Therapy (ACT) for Cancer Treatment.

  2016cites this paper
• Natural killer cells: the journey from puzzles in biology to treatment of cancer.

  2015cites this paper
• NK Cell-based Immunotherapies in Pediatric Oncology

  2015cites this paper
• Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies

  2015cites this paper
• Combinatorial therapeutic vaccination strategies for hematologic malignancies in the early period following experimental autologous hematopoietic stem cell transplantation

  2014cites this paper
• Natural Killer Cells for Cancer Immunotherapy: Pluripotent Stem Cells-Derived NK Cells as an Immunotherapeutic Perspective

  2014influential citation
• Hunting for clinical translation with innate-like immune cells and their receptors

  2014cites this paper
• Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology

  2013cites this paper
• haploidentical NK cells in cancer patients Successful adoptive transfer and in vivo expansion of human

  2012cites this paper
• Natural killer cell lines in tumor immunotherapy

  2012cites this paper
• In vitro determination and functional maturation of natural killer cells from umbilical cord blood progenitor cells

  2012cites this paper
• Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders

  2012cites this paper
• Expansion and genetic modification of human natural killer cells for adoptive immunotherapy of cancer

  2012cites this paper
• Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma.

  2011cites this paper
• A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

  2011cites this paper
• Psychoendokrinologie und Psychoimmunologie in der Onkologie

  2011cites this paper
• Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells.

  2011cites this paper
• Natural Killer Cells for Cancer Immunotherapy

  2011cites this paper
• Current Perspectives on Immunomodulation of NK Cells in Melanoma

  2011cites this paper
• NK Cells in Oncology

  2010cites this paper
• Allogeneic natural killer cells for refractory lymphoma

  2010cites this paper
• Natural Killer Cells and Their Role in Hematopoietic Stem Cell Transplantation

  2010cites this paper
• Immunotherapy of AML.

  2010cites this paper
• Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation.

  2009cites this paper
• Natural killer cell‐based immunotherapy in cancer: current insights and future prospects

  2009cites this paper
• Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer.

  2009cites this paper
• Autologous Large Multivalent Immunogen Vaccine in Patients With Metastatic Melanoma and Renal Cell Carcinoma

  2008cites this paper
• Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways.

  2008cites this paper
• Cytokines in Human Health

  2007cites this paper
• Human natural killer cells in health and disease

  2007cites this paper
• Evaluation of the Immunological Effects of Cytokines Administered to Patients With Cancer

  2007cites this paper
• Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

  2006cites this paper
• Placenta‐Derived Multipotent Cells Exhibit Immunosuppressive Properties That Are Enhanced in the Presence of Interferon‐γ

  2006cites this paper
• Positive and negative regulation of Natural Killer cells: therapeutic implications.

  2006cites this paper
• Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.

  2005cites this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005cites this paper
• Immunotherapeutic Approaches for the Treatment of Breast Cancer

  2004cites this paper
• Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

  2004cites this paper
• Immunological Consequences of Interleukin 12 Administration after Autologous Stem Cell Transplantation

  2004cites this paper
• IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

  2003cites this paper
• Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-α administration

  2003cites this paper
• Stress management intervention for women with breast cancer.

  2003cites this paper
• Role of Immunotherapy in Stem Cell Transplantation

  2003cites this paper
• Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

  2003cites this paper
• Psychoneuroendocrinology and psychoneuroimmunology of cancer: Plausible mechanisms worth pursuing?

  2003cites this paper
• Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity

  2003cites this paper
• Biology of Natural Killer Cells in Cancer and Infection

  2002cites this paper
• Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.

  2001cites this paper
• The Biology of Natural Killer Cells and Implications for Therapy of Human Disease

  2001cites this paper
• Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-α in autologous stem cell transplantation

  2001cites this paper
• The biology of natural killer cells in cancer, infection, and pregnancy.

  2001cites this paper
• Non‐MHC‐restricted cytotoxic cells: their roles in the control and treatment of leukaemias

  2001cites this paper
• Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy

  2001cites this paper
• High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends.

  2000cites this paper
• Relevance and potential of natural killer cells in stem cell transplantation.

  2000cites this paper
• Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.

  2000cites this paper
• Immunotherapy of AML: future directions

  2000cites this paper
• High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study

  2000cites this paper
• 7 . Bone marrow and stem cell transplantation for multiple myeloma

  1999cites this paper
• Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

  1999cites this paper
• Purine Receptor Lineage-SpecificHuman NK Cells Through a Purine Metabolites Suppress Proliferation of Okazaki and

  1999cites this paper
• Bone marrow and stem cell transplantation for multiple myeloma.

  1999cites this paper